Enhanced persistence with tiotropium compared with other respiratory drugs in COPD

Abstract

Persistence with tiotropium was higher compared to other inhaled respiratory drugs in COPD in clinical practice.

The Influence of Receptor Kinetics on the Onset and Duration of Action and the Therapeutic Index of NVA237 and Tiotropium

“…Important features of an ideal LAMA for use in COPD include strong selectivity for muscarinic type 3 (M 3 ) receptors, long duration of action (preferably 24 h), fast onset of action, and the ability to deliver clinically meaningful bronchodilation with a reassuring safety profile (Donohue, 2005;Vogelmeier and Banerji, 2011; http://www.goldcopd.org/guidelines-globalstrategy-for-diagnosis-management.html). A long duration of action implies both prolonged efficacy (Tashkin, 2005) and a once-daily dosage regimen that has the potential to boost patient compliance (Smith et al, 1996;Breekveldt-Postma et al, 2007;Tamura and Ohta, 2007). It has also been proposed that bronchodilators with a long duration of action offer a relatively consistent improvement in airway caliber over time, in contrast to the peaks and troughs that might arise with bronchodilators that are dosed twice daily (Beeh and Beier, 2010).…”

Zalecenia Polskiego Towarzystwa Chorób Płuc Dotyczące Rozpoznawania i Leczenia Przewlekłej Obturacyjnej Choroby Płuc

“…W badaniu holenderskim analizującym roczne stosowanie leków u ponad 2 milionów chorych na POChP wykazano, że chorzy leczeni tiotropium 2-3 razy rzadziej przerywali leczenie długo-trwałe w porównaniu z grupami osób stosujących ipratropium, długo działające leki b 2 -agonistyczne (LABA, long-acting b2-agonist) lub LABA w połą-czeniu z wziewnym glikokortykosteroidem [88].…”

Adherence to Therapy in Chronic Obstructive Pulmonary Disease

“…Breekveldt-Postma et al (Breekveldt-Postma et al, 2007) evaluated medication persistence among COPD patients in the first therapy year; new users of tiotropium, ipratropium, LABA and a fixed combination of LABA and ICS (LABA + ICS) were included in their study. The persistence was the highest, 37%, with tiotropium.…”

“…According to our evaluations, the dosing frequency of respiratory drugs is one of the most important factors affecting non-adherence in patients with COPD (Agh et al, 2011;WHO, 2003). As a partial result of the daily drug doses, a significant difference has been shown in the adherence rates between the different respiratory drug classes (Apter et al, 1998;Breekveldt-Postma et al, 2007;Laforest et al, 2010). Tiotropium, a once-daily inhaled drug, may enhance adherence compared with other inhaled respiratory medications that are dosed more times daily.…”

“…Medication adherence may increase if the prescribing physician is a specialist instead of a general practitioner (Lau et al, 1996). Furthermore, periodic visits, closer follow-up and hospitalisation may also have increasing effects on patient cooperation (Breekveldt-Postma et al, 2007).…”